Document is current
Any future updates will be listed below
-
Authors
Vdovin, Alexander https://orcid.org/0000-0003-0810-4659
Jelinek, Tomas
Zihala, David
Sevcikova, Tereza
Durech, Michal https://orcid.org/0000-0002-4054-4315
Sahinbegovic, Hana
Snaurova, Renata https://orcid.org/0000-0002-6979-844X
Radhakrishnan, Dhwani
Turi, Marcello https://orcid.org/0000-0002-8760-1794
Chyra, Zuzana
Popkova, Tereza
Venglar, Ondrej
Hrdinka, Matous https://orcid.org/0000-0002-2981-2825
Hajek, Roman
Simicek, Michal https://orcid.org/0000-0003-2388-2723
-
Funding
Funding for this research was provided by:
Grantová Agentura České Republiky (GA CR 21-21413S, 19-25354Y)
- License Information
-
More Information
Article History
Received: 30 August 2021
Accepted: 31 October 2022
First Online: 10 November 2022
Competing interests
: R.H. has had a consultant or advisory relationship with Janssen, Amgen, Celgene, AbbVie, BMS, Novartis, PharmaMar, and Takeda; has received honoraria from Janssen, Amgen, Celgene, BMS, PharmaMar, and Takeda; has received research funding from Janssen, Amgen, Celgene, BMS, Novartis, and Takeda. All additional authors declare no conflicts of interest.
